Trials / Withdrawn
WithdrawnNCT00606099
Efficacy and Safety of Telbivudine in Patients With Chronic Hepatitis B
A 26 Week Randomized, Open Label, Multi-center Study of the Efficacy and Safety of Telbivudine 600 mg Once Daily Versus Adefovir Dipivoxil 10mg Once Daily in Subjects With Compensated Chronic Hepatitis B and Sub-optimal Response to at Least 48 Weeks of Adefovir Dipivoxil 10 mg
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to evaluate the efficacy and safety of telbivudine 600mg versus adefovir dipivoxil 10mg in patients with compensated chronic hepatitis B.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | telbivudine | To compare the rate and pattern of treatment-emergent Hepatitis B virus (HBV) viral genotypic mutations after 24 weeks of treatment. |
| DRUG | adefovir dipivoxil | Active Comparator |
Timeline
- Start date
- 2007-11-01
- Primary completion
- 2009-11-01
- First posted
- 2008-02-01
- Last updated
- 2012-05-02
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00606099. Inclusion in this directory is not an endorsement.